June 18, 2026. 6 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score.
The DEA placed 3-methoxyphencyclidine, a dissociative anesthetic with no accepted medical use, into Schedule I, impacting any potential research involving this substance and clarifying its legal status separate from cannabis.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
The DEA temporarily placed bromazolam, a benzodiazepine sometimes found as adulterant in illicit cannabis products, into Schedule I, impacting prescribing, dispensing, and research involving the substance.
Read more →The DEA placed five benzodiazepine analogs into Schedule I, impacting potential clinical use and creating legal restrictions for clinicians and patients considering these substances as alternatives or adjuncts to cannabis therapies.
Read more →Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA temporarily placed 2-fluorodeschloroketamine into Schedule I, potentially impacting research and clinical use should this substance be considered alongside or as an alternative to cannabinoid therapies for similar conditions.
Read more →Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I
The DEA placed 4-fluoroamphetamine into Schedule I, a classification impacting research potential and potentially influencing regulations surrounding novel psychoactive cannabinoids with similar chemical structures.
Read more →The DEA placed potent synthetic opioids N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, impacting cannabis clinicians who may encounter patients with co-prescribed medications or polysubstance use disorders.
Read more →Digest-Level Clinical Commentary
Clinical Reflection on Recent DEA Scheduling Actions The clustering of these enforcement actions against novel synthetic drugs and benzodiazepam analogues underscores the DEA’s sustained focus on unregulated designer compounds rather than cannabis itself, which signals a potential regulatory environment where cannabis medicine can develop with somewhat reduced pressure from synthetic drug scheduling cascades. However, the continued scheduling of benzodiazepam analogues like etizolam and flualprazolam—compounds sometimes used off-label or in combination with cannabinoids for anxiety management—suggests clinicians should remain cautious about recommending cannabis as an alternative to benzodiazepines without robust controlled trial evidence, particularly since these newer synthetics persist in unregulated markets where patients might self-medicate. For cannabis medicine practitioners, this regulatory activity reinforces the importance of staying within evidence-
These regulatory actions reflect an ongoing effort to address emerging synthetic drugs that are being synthesized and distributed to circumvent existing controlled substance laws. The items demonstrate a pattern of scheduling novel analogs and derivatives of established drugs of abuse, including phencyclidine derivatives, benzodiazepines, ketamine analogs, amphetamines, and opioid-like compounds. From a clinical standpoint, this scheduling activity underscores the need for heightened awareness of unfamiliar psychoactive substances that may present with atypical toxidromes or unpredictable clinical effects compared to their parent compounds.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
